MTHFD2 and cancer: The high expression of MTHFD2 is also correlated with the shorter survival of several cancers, including breast cancer, colorectal cancer, kidney cancer, and liver cancer (20–23), thus becoming a promising prognostic biomarker and therapeutic target (24).